{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:05:00Z","timestamp":1784268300619,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02391-3","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:23:50Z","timestamp":1784258630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 2"],"prefix":"10.1007","volume":"28","author":[{"given":"Tanawat","family":"Attachaipanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin K","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"13","key":"2391_CR1","first-page":"e771","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2025;151(13):e771\u2013862.","journal-title":"Circulation"},{"issue":"10","key":"2391_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"An international randomized","year":"1993","unstructured":"An international randomized. trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673\u201382.","journal-title":"N Engl J Med"},{"issue":"9282","key":"2391_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","volume":"358","author":"Efficacy","year":"2001","unstructured":"Efficacy. safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358(9282):605\u201313.","journal-title":"Lancet"},{"issue":"14","key":"2391_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477\u201388.","journal-title":"N Engl J Med"},{"issue":"38","key":"2391_CR5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"3","key":"2391_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/eurheartj\/ehm616","volume":"29","author":"RJ Peters","year":"2008","unstructured":"Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J. 2008;29(3):324\u201331.","journal-title":"Eur Heart J"},{"issue":"2","key":"2391_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"4","key":"2391_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIRCINTERVENTIONS.109.920868","volume":"3","author":"PL S\u00e1nchez","year":"2010","unstructured":"S\u00e1nchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv. 2010;3(4):297\u2013307.","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"2391_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehl461","volume":"28","author":"F Fern\u00e1ndez-Avil\u00e9s","year":"2007","unstructured":"Fern\u00e1ndez-Avil\u00e9s F, Alonso JJ, Pe\u00f1a G, Blanco J, Alonso-Briales J, L\u00f3pez-Mesa J, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J. 2007;28(8):949\u201360.","journal-title":"Eur Heart J"},{"issue":"15","key":"2391_CR10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","volume":"368","author":"PW Armstrong","year":"2013","unstructured":"Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379\u201387.","journal-title":"N Engl J Med"},{"issue":"26","key":"2391_CR11","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1056\/NEJMoa0808276","volume":"360","author":"WJ Cantor","year":"2009","unstructured":"Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"2391_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jacc.2009.08.007","volume":"55","author":"E B\u00f8hmer","year":"2010","unstructured":"B\u00f8hmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55(2):102\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2391_CR13","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jacc.2007.01.093","volume":"49","author":"CM Gibson","year":"2007","unstructured":"Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49(23):2238\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"9296","key":"2391_CR14","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","volume":"358","author":"H White","year":"2001","unstructured":"White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358(9296):1855\u201363.","journal-title":"Lancet"},{"issue":"4","key":"2391_CR15","first-page":"614","volume":"82","author":"GL Sardi","year":"2013","unstructured":"Sardi GL, Lindsay J, Waksman R. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy. Catheter Cardiovasc Interv. 2013;82(4):614\u201320.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"2391_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550\u20136.","journal-title":"Arch Intern Med"},{"issue":"5","key":"2391_CR17","doi-asserted-by":"publisher","first-page":"e011183","DOI":"10.1161\/JAHA.118.011017","volume":"8","author":"Y Numasawa","year":"2019","unstructured":"Numasawa Y, Inohara T, Ishii H, Yamaji K, Kohsaka S, Sawano M, et al. Comparison of outcomes after percutaneous coronary intervention in elderly patients, including 10 628 nonagenarians: insights from a Japanese nationwide registry (J-PCI Registry). J Am Heart Assoc. 2019;8(5):e011183.","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"2391_CR18","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.jacc.2007.01.066","volume":"49","author":"AH Skolnick","year":"2007","unstructured":"Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV Jr., Ohman EM, et al. Characteristics, management, and outcomes of 5,557 patients age\u2009>\u2009or =\u200990 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol. 2007;49(17):1790\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2391_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jcin.2017.03.051","volume":"10","author":"AC Sawant","year":"2017","unstructured":"Sawant AC, Josey K, Plomondon ME, Maddox TM, Bhardwaj A, Singh V, et al. Temporal trends, complications, and predictors of outcomes among nonagenarians undergoing percutaneous coronary intervention: insights from the veterans affairs clinical assessment, reporting, and tracking program. JACC Cardiovasc Interv. 2017;10(13):1295\u2013303.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"2391_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","volume":"44","author":"F Andreotti","year":"2023","unstructured":"Andreotti F, Geisler T, Collet JP, Gigante B, Gorog DA, Halvorsen S, et al. Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis. Eur Heart J. 2023;44(4):262\u201379.","journal-title":"Eur Heart J"},{"issue":"1","key":"2391_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0003319716629541","volume":"68","author":"Z Liu","year":"2017","unstructured":"Liu Z, Silvain J, Kerneis M, Barth\u00e9l\u00e9my O, Payot L, Choussat R, et al. Intravenous enoxaparin versus unfractionated heparin in elderly patients undergoing primary percutaneous coronary intervention: an analysis of the randomized ATOLL trial. Angiology. 2017;68(1):29\u201339.","journal-title":"Angiology"},{"issue":"4","key":"2391_CR22","doi-asserted-by":"publisher","first-page":"e008671","DOI":"10.1161\/CIRCINTERVENTIONS.119.008671","volume":"13","author":"A Wester","year":"2020","unstructured":"Wester A, Attar R, Mohammad MA, Isma N, James S, Omerovic E, et al. Bivalirudin versus heparin monotherapy in elderly patients with myocardial infarction: a prespecified subgroup analysis of the validate-swedeheart trial. Circ Cardiovasc Interv. 2020;13(4):e008671.","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"2391_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10557-020-06937-7","volume":"34","author":"S Meng","year":"2020","unstructured":"Meng S, Xu J, Guo L, Huang R. Clinical outcomes of bivalirudin versus heparin in elderly patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2020;34(1):101\u201311.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"2391_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.recesp.2013.10.010","volume":"67","author":"A Ariza-Sol\u00e9","year":"2014","unstructured":"Ariza-Sol\u00e9 A, Formiga F, Lorente V, S\u00e1nchez-Salado JC, S\u00e1nchez-Elvira G, Roura G, et al. Efficacy of bleeding risk scores in elderly patients with acute coronary syndromes. Rev Esp Cardiol (Engl Ed). 2014;67(6):463\u201370.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2391_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjcard.2024.03.022","volume":"219","author":"AF Marschall","year":"2024","unstructured":"Marschall AF, Duarte Torres J, Biscotti Rod\u00edl B, G\u00f3mez S\u00e1nchez I, Basabe Velasco E, Ramos Alejos-Pita C, et al. PRECISE-DAPT, ARC-HBR, or simplified clinical evaluation for the prediction of major bleeding after percutaneous coronary intervention in older patients. Am J Cardiol. 2024;219:103\u20139.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2391_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","volume":"51","author":"JM Ruiz-Nodar","year":"2008","unstructured":"Ruiz-Nodar JM, Mar\u00edn F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51(8):818\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2391_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21(2):192\u20133.","journal-title":"Europace"},{"key":"2391_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2016.08.089","volume":"223","author":"M Kowalewski","year":"2016","unstructured":"Kowalewski M, Suwalski P, Raffa GM, S\u0142omka A, Kowalkowska ME, Szwed KA, et al. Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. Int J Cardiol. 2016;223:186\u201394.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2391_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4244\/EIJY14M06_07","volume":"11","author":"WJ Dewilde","year":"2015","unstructured":"Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens T, et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 2015;11(4):381\u201390.","journal-title":"EuroIntervention"},{"issue":"6","key":"2391_CR30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1253\/circj.CJ-11-1206","volume":"76","author":"H Lahtela","year":"2012","unstructured":"Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemel\u00e4 M, Vikman S, et al. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J. 2012;76(6):1363\u20138.","journal-title":"Circ J"},{"issue":"9","key":"2391_CR31","doi-asserted-by":"publisher","first-page":"e000035","DOI":"10.1161\/HCV.0000000000000035","volume":"11","author":"PJ Mason","year":"2018","unstructured":"Mason PJ, Shah B, Tamis-Holland JE, Bittl JA, Cohen MG, Safirstein J, et al. An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American heart association. Circ Cardiovasc Interv. 2018;11(9):e000035.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"2391_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jjcc.2016.04.015","volume":"69","author":"G Gallego-S\u00e1nchez","year":"2017","unstructured":"Gallego-S\u00e1nchez G, Gallardo-L\u00f3pez A, C\u00f3rdoba-Soriano JG, Guti\u00e9rrez-D\u00edez A, Melehi D, Barrionuevo-S\u00e1nchez MI, Jim\u00e9nez-Mazuecos J. Safety of transradial diagnostic cardiac catheterization in patients under oral anticoagulant therapy. J Cardiol. 2017;69(3):561\u20134.","journal-title":"J Cardiol"},{"issue":"4","key":"2391_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1378\/chest.08-1425","volume":"135","author":"S Manzano-Fern\u00e1ndez","year":"2009","unstructured":"Manzano-Fern\u00e1ndez S, Mar\u00edn F, Pastor-P\u00e9rez FJ, Caro C, Cambronero F, Lacunza J, et al. Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting. Chest. 2009;135(4):983\u201390.","journal-title":"Chest"},{"issue":"9","key":"2391_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4244\/EIJV8I9A162","volume":"8","author":"P Vranckx","year":"2013","unstructured":"Vranckx P, Verheugt FW, de Maat MP, Ulmans VA, Regar E, Smits P, et al. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention. 2013;8(9):1052\u201360.","journal-title":"EuroIntervention"},{"issue":"2","key":"2391_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1160\/TH15-01-0061","volume":"114","author":"P Vranckx","year":"2015","unstructured":"Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, et al. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost. 2015;114(2):258\u201367.","journal-title":"Thromb Haemost"},{"issue":"2","key":"2391_CR36","doi-asserted-by":"publisher","first-page":"e009949","DOI":"10.1161\/CIRCINTERVENTIONS.120.009949","volume":"14","author":"JG C\u00f3rdoba-Soriano","year":"2021","unstructured":"C\u00f3rdoba-Soriano JG, Oteo JF, Guti\u00e9rrez-D\u00edez A, Escudero-D\u00edaz A, Gallardo-L\u00f3pez A, Portero-Portaz JJ, et al. Percutaneous Coronary Intervention Without Interruption of Oral Anticoagulation. Circ Cardiovasc Interv. 2021;14(2):e009949.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"2391_CR37","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376.","journal-title":"Europace"},{"issue":"3","key":"2391_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","volume":"1","author":"L Turco","year":"2019","unstructured":"Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019;1(3):227\u201339.","journal-title":"JHEP Rep"},{"issue":"31","key":"2391_CR39","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632\u201353.","journal-title":"Eur Heart J"},{"issue":"9","key":"2391_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.amjcard.2020.01.052","volume":"125","author":"DY Lu","year":"2020","unstructured":"Lu DY, Steitieh D, Feldman DN, Cheung JW, Wong SC, Halazun H, et al. Impact Of cirrhosis On 90-day outcomes after percutaneous coronary intervention (from A Nationwide Database). Am J Cardiol. 2020;125(9):1295\u2013304.","journal-title":"Am J Cardiol"},{"key":"2391_CR41","doi-asserted-by":"publisher","first-page":"117954682090149","DOI":"10.1177\/1179546820901491","volume":"14","author":"DY Lu","year":"2020","unstructured":"Lu DY, Saybolt MD, Kiss DH, Matthai WH, Forde KA, Giri J, Wilensky RL. One-year outcomes of percutaneous coronary intervention in patients with end-stage liver disease. Clin Med Insights Cardiol. 2020;14:1179546820901491.","journal-title":"Clin Med Insights Cardiol"},{"issue":"3","key":"2391_CR42","doi-asserted-by":"publisher","first-page":"e005727","DOI":"10.1161\/CIRCINTERVENTIONS.117.005727","volume":"11","author":"G Tirado-Conte","year":"2018","unstructured":"Tirado-Conte G, Rod\u00e9s-Cabau J, Rodr\u00edguez-Olivares R, Barbanti M, Lhermusier T, Amat-Santos I, et al. Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis. Circ Cardiovasc Interv. 2018;11(3):e005727.","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"2391_CR43","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camm\u00e0 C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253\u2013e604.","journal-title":"Gastroenterology"},{"issue":"4","key":"2391_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1592\/phco.26.4.452","volume":"26","author":"TH Kiser","year":"2006","unstructured":"Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and\/or renal dysfunction. Pharmacotherapy. 2006;26(4):452\u201360.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2391_CR45","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s10620-019-05939-2","volume":"65","author":"SK Vuyyuru","year":"2020","unstructured":"Vuyyuru SK, Singh AD, Gamanagatti SR, Rout G, Gunjan D, Shalimar. A randomized control trial of thromboelastography-guided transfusion in cirrhosis for high-risk invasive liver-related procedures. Dig Dis Sci. 2020;65(7):2104\u201311.","journal-title":"Dig Dis Sci"},{"key":"2391_CR46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijcard.2016.11.096","volume":"228","author":"T Arai","year":"2017","unstructured":"Arai T, Yashima F, Yanagisawa R, Tanaka M, Shimizu H, Fukuda K, et al. Prognostic value of liver dysfunction assessed by MELD-XI scoring system in patients undergoing transcatheter aortic valve implantation. Int J Cardiol. 2017;228:648\u201353.","journal-title":"Int J Cardiol"},{"key":"2391_CR47","first-page":"101645","volume":"57","author":"M Sudo","year":"2025","unstructured":"Sudo M, Arai R, Kojima K, Tachibana E, Atsumi W, Matsumoto M, et al. Clinical implications of the MELD-XI score in patients undergoing percutaneous coronary intervention: Insights from the SAKURA PCI2 Antithrombotic registry. Int J Cardiol Heart Vasc. 2025;57:101645.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"5","key":"2391_CR48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1053\/ajkd.2001.28588","volume":"38","author":"AG Stack","year":"2001","unstructured":"Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis. 2001;38(5):992\u20131000.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2391_CR49","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0002-9149(03)00970-6","volume":"92","author":"DP Chew","year":"2003","unstructured":"Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92(8):919\u201323.","journal-title":"Am J Cardiol"},{"issue":"21","key":"2391_CR50","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/eurheartj\/ehi337","volume":"26","author":"JP Collet","year":"2005","unstructured":"Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, L\u00f3pez-Send\u00f3n J, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb\/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005;26(21):2285\u201393.","journal-title":"Eur Heart J"},{"issue":"5","key":"2391_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.amjcard.2004.11.003","volume":"95","author":"DP Chew","year":"2005","unstructured":"Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb\/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol. 2005;95(5):581\u20135.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2391_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jcin.2009.05.018","volume":"2","author":"R Mehran","year":"2009","unstructured":"Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009;2(8):748\u201357.","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"2391_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jcin.2011.06.012","volume":"4","author":"AJ Saltzman","year":"2011","unstructured":"Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2011;4(9):1011\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"2391_CR54","doi-asserted-by":"publisher","first-page":"e005628","DOI":"10.1161\/CIRCINTERVENTIONS.117.005628","volume":"11","author":"JB Washam","year":"2018","unstructured":"Washam JB, Kaltenbach LA, Wojdyla DM, Patel MR, Klein AJ, Abbott JD, Rao SV. Anticoagulant use among patients with end-stage renal disease undergoing percutaneous coronary intervention: an analysis from the national cardiovascular data registry. Circ Cardiovasc Interv. 2018;11(2):e005628.","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"2391_CR55","first-page":"724","volume":"90","author":"D Sukul","year":"2017","unstructured":"Sukul D, Seth M, Schreiber T, Khandelwal A, Cannon LA, LaLonde TA, Gurm HS. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium. Catheter Cardiovasc Interv. 2017;90(5):724\u201332.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"10","key":"2391_CR56","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1345\/aph.1Q177","volume":"45","author":"LV Tsu","year":"2011","unstructured":"Tsu LV, Dager WE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother. 2011;45(10):1185\u201392.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2391_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397\u2013404.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"2391_CR58","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","volume":"287","author":"MK Higashi","year":"2002","unstructured":"Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690\u20138.","journal-title":"JAMA"},{"key":"2391_CR59","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2011-07-365502","volume":"119","author":"C Moreau","year":"2011","unstructured":"Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2011;119:861\u20137.","journal-title":"Blood"},{"issue":"8","key":"2391_CR60","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106\u201312.","journal-title":"Blood"},{"issue":"4","key":"2391_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2710.2011.01317.x","volume":"37","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, et al. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther. 2012;37(4):481\u20135.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"2391_CR62","doi-asserted-by":"publisher","first-page":"e196835","DOI":"10.1001\/jamanetworkopen.2019.6835","volume":"2","author":"BJ Mortazavi","year":"2019","unstructured":"Mortazavi BJ, Bucholz EM, Desai NR, Huang C, Curtis JP, Masoudi FA, et al. Comparison of machine learning methods with national cardiovascular data registry models for prediction of risk of bleeding after percutaneous coronary intervention. JAMA Netw Open. 2019;2(7):e196835.","journal-title":"JAMA Netw Open"},{"issue":"3Part B","key":"2391_CR63","first-page":"102497","volume":"4","author":"KB Fischer","year":"2025","unstructured":"Fischer KB, Valencia DN, Reddy A, Khouzam JP, Karabatak ZF, Reddivari A, et al. Effects of artificial intelligence clinical decision support tools on complications following percutaneous coronary intervention. J Soc Cardiovasc Angiogr Interv. 2025;4(3Part B):102497.","journal-title":"J Soc Cardiovasc Angiogr Interv"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02391-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:26:21Z","timestamp":1784265981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02391-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02391-3","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}